ADVERTISEMENT
Search

Transitions Magazine

Transitions is published bi-monthly for members of the APhA New Practitioner Network. The online newsletter contains information focused on life inside and outside pharmacy practice, providing guidance on various areas of professional, personal, and practice development. Each issue includes in-depth articles on such topics as personal financial management, innovative practice sites, career profiles, career development tools, residency and postgraduate programs, and more.

FDA approves higher dosage of naloxone nasal spray FDA approves higher dosage of naloxone nasal spray

FDA approves higher dosage of naloxone nasal spray

0 20313
On April 30, FDA announced the approval of a higher dosage of naloxone hydrochloride nasal spray (Kloxxado—Hikma Pharmaceuticals) to treat opioid overdose. The newly approved product delivers 8 mg of naloxone into the nasal cavity, compared with previously approved 2- and 4-mg naloxone nasal spray products.
Advertisement
Advertisement
Advertisement
Advertisement

ADVERTISEMENT